Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05121493 · ClinicalTrials.gov registry record · NA

Study of Platelet Rich Plasma Drops to Moderate Clinically Significant Dry Eye

A NA study, sponsored by University of Rochester.

Not yet
Registry status
NA
Development phase
15
Enrollment target

NCT05121493: Clinical Trial NA study, sponsored by University of Rochester.

NCT05121493 is a NA study that has not yet begun recruiting, run by University of Rochester. The registered enrollment target is 15 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05121493, a NA study, has not yet begun recruiting, sponsored by University of Rochester.

NOT YET RECRUITING
Registry status
NA
Development phase
15 participants
Enrollment target

Study Summary

This is a single center double-masked study with up to four visits. Subjects who have been diagnosed with dry-eye syndrome at Flaum Eye Institute will be enrolled. The purpose of the study is to determine if using platelet rich plasma drops can improve clinically significant dry eye in patients and determine if there is a difference with using two different uses of the plasma tear drops: platelet rich plasma tears and plasma tears without platelets.

Interventions

  • OTHER Platelet Poor Plasma Tear Drops
  • OTHER Platelet Rich Plasma Tear Drops

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2025-10-15
Est. Completion 2026-12-15
Phase NA
University of Rochester

636 total trials

What is known before NCT05121493 opens enrollment

NCT05121493 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).

The record links to 0 conditions, and to 2 interventions - of which Platelet Poor Plasma Tear Drops is the first listed.

NCT05121493 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT05121493 about?

NCT05121493 is a clinical study titled "Study of Platelet Rich Plasma Drops to Moderate Clinically Significant Dry Eye". This is a single center double-masked study with up to four visits. Subjects who have been diagnosed with dry-eye syndrome at Flaum Eye Institute will be enrolled. The purpose of the study is to determine if using platelet rich plasma drops can improve clinically significant dry eye in patients and ...

What is the current status of trial NCT05121493?

This trial is currently not yet recruiting. It is a NA study. The enrollment target is 15 participants. The study started on 2025-10-15. Estimated completion is 2026-12-15.

What interventions are being tested in trial NCT05121493?

The interventions under investigation include: Platelet Poor Plasma Tear Drops (OTHER), Platelet Rich Plasma Tear Drops (OTHER).

Who is sponsoring clinical trial NCT05121493?

This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT05121493's enrollment target sits among peer trials

15 1881st of 2000 higher than 92 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01889381 · 15 participants · Phase 2

    Human Craniomaxillofacial Allotransplantation

  • NCT02530073 · 15 participants · NA

    Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH

  • NCT02535936 · 15 participants · NA

    Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy

  • NCT02918474 · 15 participants · NA

    Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05121493, the US trial registry maintained by the National Library of Medicine. NCT05121493 (small enrollment · none site footprint · not yet recruiting) retrieved and formatted by PlainTrial, see methodology.